Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy.

Velicu, Simona; Han, Yu; Ulasov, Ilya; Brown, Ian E; El Andaloussi, Abdel; Gajewski, Thomas F; Lesniak, Maciej S

Velicu, Simona; Han, Yu; Ulasov, Ilya; Brown, Ian E; El Andaloussi, Abdel; Gajewski, Thomas F; Lesniak, Maciej S.

Affiliation

Velicu S; Division of Neurosurgery, The University of Chicago, Pritzker School of Medicine, 5841 S. Maryland Ave-MC 3026, Chicago, IL 60637, USA.

J Neuroimmunol ; 174(1-2): 74-81, 2006 May.

Article in En | MEDLINE | ID: mdl-16504307

Subject(s)

Abdominal Neoplasms/therapy; Antigens, Neoplasm/physiology; Brain Neoplasms/therapy; Cross-Priming/physiology; Immunotherapy/methods; Melanoma, Experimental/therapy; Abdominal Neoplasms/immunology; Animals; Brain Neoplasms/immunology; CD8-Positive T-Lymphocytes/immunology; Cell Line, Tumor; Disease Models, Animal; Interleukin-2/immunology; Lymphocyte Activation; Male; Melanoma, Experimental/immunology; Mice; Mice, Inbred C57BL; Survival Analysis; Time Factors

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Melanoma, Experimental / Brain Neoplasms / Cross-Priming / Immunotherapy / Abdominal Neoplasms / Antigens, Neoplasm Type of study: Prognostic_studies Limits: Animals Language: En Journal: J Neuroimmunol Year: 2006 Document type: Article Affiliation country: United States

Search on Google

Add to My VHL

XML

PubMed Links